Global Life Science Business Partnering (GLSBP)

Highlights of July 2022

Dr. Reddy's Labs acquires injectable product portfolio from Eton Pharma.
Aurigene inks drug discovery partnership with EQRx.
Zenara Pharma to manufacture and sell generic of Pfizer’s COVID-19 drug.
Dr Reddy's Lab has inked a licensing pact with the New Jersey-based Slayback Pharma to acquire rights in Brimonidine Tartrate Ophthalmic Solution 0.025 per cent.
Sun Pharmaceutical and Cassiopea, a subsidiary of Cosmo Pharmaceuticals announced the signing of License and Supply Agreements for WINLEVI expanding the territory to include Japan, Australia, New Zealand, Brazil, Mexico and Russia.
Cipla Health Limited, consumer healthcare arm of the company has signed definitive agreements for the acquisition of Endura Mass from Medinnbelle Herbalcare.
Syros acquires TYME and announces $130 million private placement.
Valo Therapeutics acquires PeptiCHIP technology.
Orion and MSD announce global collaboration.
Innoviva to acquire La Jolla Pharma.
DKSH and Pharmanovia partner to provide meds in Southeast Asia.
Sobi in-license loncastuximab tesirine from ADC Therapeutics.
Japanese drugmaker Mitsubishi Tanabe Pharma is to sell US pharma major Eli Lilly’s diabetes drug tirzepatide in Japan following an agreement between the companies.
AstraZeneca to acquire TeneoTwo to expand blood cancer pipeline.

Updates at Aagami:

Aagami received a new assignment from an existing client.
Aagami also received 2 contract extensions (French and US clients).
Aagami is attending the Partnering Conference – BIO-Europe® 2022 (October 24–26, 2022 | Leipzig, Germany).

INFOCUS: Select opportunities available at Aagami:

For Acquisition:

Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns.

For Partnering/Licensing/ Investment:

Investment Licensing - US FDA approved portable MRI Guided Treatment, Diagnosis and Screening ($40 Million Series C Open). For Urology applications.
Licensing/Strategic Partnership: Next-gen AI powered imaging to pinpoint the IVF +/- 12 hour window of opportunity to implant the embryo. First solution that supports the science of uterine receptivity vs. a physician's estimates or inaccurate ultrasound. Market Launch early 2024.
Series B Open- Novel Evolution of Portable MRI and Robotics for Neurology treatments like Strokes and TBI.
Technology Licensing: Easy to apply Microneedle Array Patch (MAP) system to deliver drugs, vaccines; better immune response than injection. A painless and efficient replacement to Syringes.
Midwest US based Pharma’s First-in-Class Non-Opioid Analgesic for both chronic and acute Pain Relief – Seeking funding/licensing/co-development partnerships.